OLOLADE ADEKOYA: Open Payments
NPI 1144686569 · GLEN BURNIE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,394 in 101 payments from 18 companies in 2025. Trend: 2023 $46 · 2024 $2,056 · 2025 $3,394
Food & beverage: $3,394
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 24 | $790 |
| Otsuka America Pharmaceutical, Inc. | 10 | $512 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 16 | $479 |
| Neurocrine BioSciences, Inc. | 4 | $223 |
| Axsome Therapeutics, Inc. | 8 | $218 |
| Supernus Pharmaceuticals, Inc. | 6 | $198 |
| E.R. Squibb & Sons, L.L.C. | 7 | $184 |
| Lundbeck LLC | 8 | $181 |
| Janssen Pharmaceuticals, Inc | 1 | $118 |
| Indivior Inc. | 3 | $117 |
Products named: VRAYLAR, CAPLYTA, REXULTI, ABILIFY MAINTENA, INGREZZA, Auvelity, Qelbree, COBENFY.
Industry payments across MD — which companies pay providers there.
